Rigel Pharmaceuticals has entered an exclusive global license agreement with Arvinas and Pfizer to develop, manufacture and commercialize VEPPANU (vepdegestrant), the first FDA-approved oral PROTAC ...

Arvinas and Pfizer to receive $85 million in upfront and transition payments with potential for additional $320 million in development, ...

Rigel Pharmaceuticals Inc. RIGL stock is trading higher on Tuesday as the company is entering an exclusive global licensing ...

Pfizer (NYSE:PFE) and Arvinas have transferred global development and commercialization rights for VEPPANU (vepdegestrant) to ...

Pfizer and Arvinas have landed a buyer for the newly approved breast cancer med Veppanu, selling an exclusive global license to Rigel Pharmaceuticals for $85 million upfront and potentially hundreds ...

Shares of Rigel Pharmaceuticals RIGL have rallied 76.7% in the past three months. This stock price rally can be attributed to growing investor confidence regarding the strong growth of the company’s ...

Veppanu leverages PROTAC-mediated ubiquitin–proteasome degradation to eliminate mutant estrogen receptor, aiming to bypass ESR1-driven endocrine resistance rather than merely inhibiting receptor ...

Rigel Pharmaceuticals said on Tuesday it has struck a global licensing deal for Arvinas and Pfizer's recently ​approved breast cancer drug, marking Rigel's fourth ‌commercial product on the market.

Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) jumped 20.9% in August, according to data provided by S&P Global Market Intelligence as investors in the biotech become more comfortable with the ...

(RTTNews) - Shares of Rigel Pharmaceuticals, Inc. (RIGL) are slipping over 11% in extended session on Monday after the company said it has received guidance from the U.S. Food and Drug ...

NEW YORK (AP) -- Shares of Rigel Therapeutics Inc. lost more than a third of their value Friday on mixed results from a late-stage clinical trial of a rheumatoid arthritis drug the company helped ...